r&d

The study by Stanford Institute for Economic Policy Research uses the pharmaceutical industry as a case study, and suggests that the economic return on publicly funded basic research is substantial but on a time dimension that may be greater than most state and local leaders are anticipating.

The White House Office of Science & Technology Policy report offers information on federal research activity and investment in each state. The 700-page on-line publication provides a level of detail for federal research and development in each state.

Is public R&D spending complementary and thus “additional” to private R&D spending, or does it
substitute for and tend to “crowd out” private R&D? Conflicting answers are given to this question. The authors survey the body of available econometric evidence accumulated over the past 35 years.

This article critically reviews the literature on the economic benefits of publicly funded basic research. According to the authors, from the literature based on surveys and on case studies, it is clear that the benefits from public investment in basic research can take a variety of forms.

The report provides an assessment of the economic value of medical research to challenge economists who are inclined to be skeptical about the efficiency of the “market” for health services in
general and government directed medical research in particular.

SSTIs President and Research Director co-authored the report that identifies research and development (R&D) as a fundamental economic development building block in the new economy and calls on states to invest in universities and the private sector as ways to ensure that they have strong R&D bases.

The data brief from the National Science Foundation reports that two-thirds of all U.S. research and development (R&D) expenditures in 1997 were concentrated in just ten states. The brief also graphically presents the ten-year trends for state R&D expenditures. Also of note are the state rankings by R&D intensity, as measured by R&D expenditures as a percentage of gross state product.

Battelle Memorial Institute and the National Science Foundation report indicates total research and development investment in the United States was strong in 2000, and is expected to increase about five percent in 2001. Battelle predicts that industry will continue to emphasize various forms of partnering and collaborations, including relationships with other industry, federal laboratories and international facilities.

The report introduces the U.S. Corporate research and development (R&D) data series to provide new information and context on the R&D activity of the Nation’s top 500 R&D spending corporations. Data is based on the Standard and Poor’s Compustat database.

The report expands and updates the information contained in an earlier study based upon 1992 data. It examines a wide range of practical questions and policy concerns arising from the rapid growth of the
global R&D enterprise.